Prostate Cancer

Positive results reported for telomerase cancer vaccine clinical trial

Published in Gene Therapy Weekly, January 15th, 2004

Geron Corp. (GERN) announced the presentation of additional positive preliminary results from a phase I/II clinical trial of a telomerase therapeutic vaccine for metastatic prostate cancer at Duke University Medical Center.

The results were presented at the recent American Society of Hematology annual meeting by the principal investigator on the clinical trial, Johannes Vieweg, MD, associate professor of urology and associate professor of immunology at Duke.

Vieweg's presentation reported that all but one of the patients in the clinical trial evaluated so far showed strong telomerase-specific cellular immune responses, that no patients exhibited any...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-01-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry